Comparative Pharmacology
Head-to-head clinical analysis: OMIDRIA versus PROLENSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMIDRIA versus PROLENSA.
OMIDRIA vs PROLENSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OMIDRIA is a fixed-dose combination of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist that causes vasoconstriction.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and angiogenesis in the eye.
1 mL of the fixed-dose combination (ketorolac 0.45% / phenylephrine 1%) administered intracamerally as a single dose at the time of cataract surgery.
Adults: 1 drop in affected eye(s) twice daily (morning and evening) for 2 weeks.
None Documented
None Documented
Ketorolac: terminal half-life of 5.3 hours (range 3.8-8.2 hours) in adults; phenylephrine: terminal half-life of 2-3 hours. Clinically, ketorolac's half-life supports twice-daily dosing.
Terminal elimination half-life is approximately 1.5 hours for the ocular route; after systemic absorption, half-life is about 4.5 hours. The short half-life limits systemic exposure but requires multiple daily dosing for sustained ocular effect.
Renal elimination of ketorolac accounts for approximately 91% of the dose, with approximately 60% as unchanged drug and the remainder as metabolites; phenylephrine is primarily metabolized and excreted in urine as sulfate conjugates, with <20% excreted unchanged.
Primarily renal elimination (approximately 70% of the dose as unchanged drug and metabolites), with the remainder excreted in feces via biliary secretion (approximately 30%).
Category C
Category C
Ophthalmic NSAID and Mydriatic Combination
Ophthalmic NSAID